Perrigo court case and ruling over €1.64bn tax bill has far-reaching implications

Action brought by drug firm against Revenue closely watched for implications beyond case

US pharma giant says it is disappointed by High Court judgment

Group eyeing up to 10 investments, mostly in therapeutics and medical device sectors

Judgment could have major implications well beyond the drug company

Company says third quarter saw drop in revenue as restrictions hit business

Drug company not being ‘singled out’ in dispute over tax assessment, High Court told

Tax collector maintains Perrigo owes the money because of its 2013 purchase of Elan

Pharma group challenging ‘surprise’ Revenue assessment in hearing via video link

US drug company case to be heard via video link due to Covid-19 courtroom restrictions

Irish tax authorities argue sale of drug for MS should have been treated as capital gain

US analyst RBC upbeat about High Court challenge to €1.64bn charge over Tysabri

Legalisation is coming, no matter what Irish policymakers may say now

Tax bill linked to sale by Elan of its stake in multiple sclerosis drug Tysabri in 2013

Perrigo has repeatedly argued it will defend its position in the tax case, and denies Elan underpaid tax on the Tysabri deal

Revenue should not have issued notice of amended assessment of liability, firm says

Theratechnologies has appointed Conor Walshe to the role of general manager

Peter Chambré and Shane Cooke to take up roles with services provider on February 1st

Pharma group understood to have filed documents to contest assessment

Listed pharmaceutical giant has signalled its intention to appeal Revenue’s tax assessment